Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Fece, de, la, Cruz, F; Varkaris, A; Patel, PS; Kushner, EW; Morales-Giron, AA; Lee, SS; Singh, A; Kim, CT; Norden, BL; Ehnstrom, S; Riedl, JM; Curtis, JM; Barnes, H; Kehlmann, AM; Chevalier, NJ; Okuma, HS; Patel, M; Wirth, LJ; Connell, B; Nugent, F; Pappas, L; Lau, K; Juric, D; Hopkins, JL; Guiley, KZ; Shokat, KM; Gulhan, DC; Parikh, AR; Corcoran, RB.
Acquired on-target alterations drive clinical resistance to p53-Y220C reactivators.
Cancer Discov. 2026; Doi: 10.1158/2159-8290.CD-25-1761
PubMed FullText FullText_MUG

 

Authors Med Uni Graz:

Riedl Jakob

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

The tumor suppressor TP53 is the most frequently altered gene in cancer, and the Y220C hotspot, found in 1.8% of TP53-mutant tumors, creates a druggable cavity that destabilizes p53. Rezatapopt, a first-in-class, orally bioavailable reactivator of Y220C-mutant p53, has demonstrated promising initial efficacy in the phase 1/2 PYNNACLE trial. We report the first clinical mechanisms of resistance to this therapeutic class. Profiling of circulating tumor DNA, tumor biopsies, and rapid autopsy specimens upon rezatapopt progression revealed multiple heterogenous secondary TP53 alterations in cis with Y220C, including: (1) DNA-binding domain mutations or frameshift/nonsense mutations that abolish transcriptional activity, and (2) mutations within the Y220C binding surface predicted to hinder drug binding. Functional modeling confirmed these double mutants eliminate p53 reactivation and target gene induction by rezatapopt. These findings establish a molecular framework for resistance to p53 Y220C reactivators and inform strategies to overcome resistance with next-generation agents.

© Med Uni Graz • Imprint